J&J hikes CEO's pay to $25.1M

Another day, another CEO pay raise. Johnson & Johnson honcho Bill Weldon (photo) nabbed a 22 percent hike in compensation in 2007. Between base salary of $1.73 million, incentive pay of $9.19 million, plus stock awards and options and various miscellaneous perks, he raked in $25.1 million in compensation. In 2006, his package amounted to $20.6 million.

Now, J&J grew sales by nearly 15 percent last year, to $61.1 billion. But profits fell by 4 percent to $10.6 billion, mostly on restructuring charges. And that sales growth came despite falling revenues from the anemia drug Procrit, which attracted safety-related scrutiny during the second half of the year. That med, along with sister products made by Amgen, are on the agenda at an FDA advisory panel today and may see sales limits as a result.

And discussion of J&J's 2007 can't leave out the company's big restructuring plan, which involves cutting up to 4,820 jobs. How, we wonder, do those pink-slipped workers feel about Weldon's raise? We know how shareholders feel: J&J stock jumped by 21 cents to $62.65 yesterday, about a dime of that after the proxy was filed.

- read the article from CNBC

ALSO: A J&J unit warned that some patients using its AIDS drug Prezista developed liver damage and others died; cautionary language about liver injuries was added to the drug's label. Article

Related Articles:
AstraZeneca's CEO sees 19% pay cut. Report
Merck chief got 80% pay hike. Report
J&J CEO talks tech. Report
J&J restructures pharma unit, laying off workers. Report 

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.